“We believe that the GlycoMark test provides important additional information to help physicians personalize patient treatment plans and drive better clinical outcomes.” Melanie Stallings, Director of Laboratory Operations of Premier Medical Laboratory Services.
NEW YORK (PRWEB) September 28, 2018
GlycoMark®, Inc. has announced a partnership with Premier Medical Laboratory Services (PMLS) to increase the availability of the GlycoMark test, the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions in patients with diabetes. With the partnership, PMLS will promote and offer the GlycoMark test to its network of physicians through its sales organization and MD DiabeticPro® laboratory services.
“As an industry leader, we strive to provide physicians with innovative solutions that enable the best possible care for patients,” said Melanie Stallings, Director of Laboratory Operations of Premier Medical Laboratory Services. “We believe that the GlycoMark test provides important additional information to help physicians personalize patient treatment plans and drive better clinical outcomes.”
Hyperglycemia, which leads to numerous diabetic vascular complications, isn’t always easily detected. Nearly 40% of patients who are deemed to be in “good control”, based on A1C glucose averages, may have significant postprandial hyperglycemia or glycemic variability. Furthermore, a periodic blood glucose is not always reliably timed or performed, and may yield inaccurate results.
“We are very pleased with our partnership with Premier Medical Laboratory. By adding the GlycoMark test to PMLS’s MD DiabeticPro menu, physicians will have increased awareness and access to the test to help improve the management of patients with diabetes,” said Hiro Ishibashi, President of GlycoMark, Inc.
GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, Asia Pacific region and the Middle East. The GlycoMark test is the only FDA cleared non-fasting blood test that detects hyperglycemia and hyperglycemic excursions occurring in the prior 1 to 2 weeks. Since its discovery, the GlycoMark Test, a quantitative test for 1,5- Anhydroglucitol (1,5-AG), has been described in more than 1,300 scientific and medical publications and is shown to be independently associated with complications of diabetes. More information is available at http://www.GlycoMark.com.
ABOUT PREMIER MEDICAL LABORATORY
Premier Medical is a highly complex, advanced diagnostic lab with multiple specialty programs and a full complement of chemistry, immunoassay and hematology testing, located in Greenville, SC. PMLS offers the following specialty tests, to provide clinicians with clinically relevant testing in order to improve patient outcomes and quality of life:
- MD HeartPro – An advanced cardiovascular profile that identifies hidden risk factors not identified by common cardiovascular testing
- MD AllergyPro – Serum based IgE testing
- MD DrugPro – A Medication Compliance Monitoring toxicology program
- MD WellnessPro – A comprehensive look at a patient’s wellness profile
- MD GeneticPro – Premier Medical’s constantly growing molecular department’s menu includes Pharmacogenomics, Hereditary Cancer Panels, Women’s Health Vaginitis/Vaginosis/STI panel, Respiratory Pathogen Panel, Gastrointestinal Pathogen Panel and Hepatitis C Genotyping.
With our partnership with GlycoMark, we would like to announce our new test panel:
- MD DiabeticPro: Glucose w eAG, Hemoglobin A1C, GlycoMark, Hemoblobin A1C/GlycoMark Ratio, Adiponectin Insulin and C-Peptide
GlycoMark is a registered trademark of GlycoMark, Inc. MD DiabeticPro is a registered trademark of PremierMedical Laboratory.